These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical appraisal of cyclophosphamide in malignant neoplasms. ATKINS HL; GREGG HG; HYMAN GA Cancer; 1962; 15():1076-80. PubMed ID: 13863097 [No Abstract] [Full Text] [Related]
26. [Our initial experience with endoxan (B 518) therapy]. PRCIC M Med Arh; 1959; 13():127-41. PubMed ID: 14434709 [No Abstract] [Full Text] [Related]
27. [Clinical experimentation with cyclophosphamide in the treatment of malignant diseases]. OLMER J; CASANOVA P Therapie; 1961; 16():755-9. PubMed ID: 14481881 [No Abstract] [Full Text] [Related]
28. A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard. NISSEN-MEYER R; HOST H Cancer Chemother Rep; 1960 Nov; 9():51-5. PubMed ID: 13729268 [No Abstract] [Full Text] [Related]
29. Filament formation in E. coli induced by azaserine and other antineoplastic agents. MAXWELL RE; NICKEL VS Science; 1954 Aug; 120(3111):270-1. PubMed ID: 13186832 [No Abstract] [Full Text] [Related]
30. A polarographic study of copper complexes with some cancer chemotherapeutic agents. CHRISTIAN GD; PURDY WC Biochim Biophys Acta; 1961 Dec; 54():587-8. PubMed ID: 13879281 [No Abstract] [Full Text] [Related]
31. [Clinico-hematological observations on the use of Enduxan in lymphomas]. JAMRA M; MILDER R Arq Oncol; 1961; 4():172-3. PubMed ID: 14451065 [No Abstract] [Full Text] [Related]
32. COLORIMETRIC METHOD FOR DETERMINATION OF URACIL MUSTARD AND RELATED ALKYLATING AGENTS. PETERING HG; VANGIESSEN GJ J Pharm Sci; 1963 Dec; 52():1159-62. PubMed ID: 14088966 [No Abstract] [Full Text] [Related]
33. Studies in the pharmacodynamics of mechlorethamine and AB 100. AUSMAN RK; CREVAR GE; HAGEDORN H; BARDOS TJ; AMBRUS JL JAMA; 1961 Nov; 178():735-8. PubMed ID: 13863314 [No Abstract] [Full Text] [Related]
34. NITROGEN MUSTARDS DERIVED FROM 3,4-DIHYDRO-2, 4-DIOXO-1(2H)-PYRIMIDINEPROPIONIC AND -BUTYRIC ACIDS. MARTINEZ AP; LEE WW; GOODMAN L J Med Chem; 1965 Mar; 8():187-9. PubMed ID: 14332657 [No Abstract] [Full Text] [Related]
35. [Evaluation of the specificity of anti-proliferative drugs. Comparison of nitrogen mustard, triethylene melamine and cyclophosphamide]. SCALTRINI GC; TOGNELLA S; CONIGLIARO S; GRIFONI V Haematol Lat; 1961; 4():411-22. PubMed ID: 14497771 [No Abstract] [Full Text] [Related]
36. Synthesis and anticancer activity of 5-diethylaminomethyl derivatives and nitrogen mustards of uracil and 2-thiouracils. Fabrissin S; de Nardo M; Nisi C; Morasca L; Dolfini E; Franchi G J Med Chem; 1976 May; 19(5):639-42. PubMed ID: 1271405 [TBL] [Abstract][Full Text] [Related]
37. [Comparative investigation of the chemotherapeutic action of N-oxide-mustard gas and other alkylating compounds in rat tumors]. DANNEBERG P; DRUCKREY H; KAISER K; LO HW; MECKE R; NIEPER HA; SCHMAHL D Arzneimittelforschung; 1956 Sep; 6(9):539-50. PubMed ID: 13373668 [No Abstract] [Full Text] [Related]
38. [ON THE POSSIBILITY OF PROLONGING THE VIABILITY OF SKIN TRANSPLANTS IN RABBITS WITH ALKYLATING SUBSTANCES]. POPOV VI; NEZDATNYI MM Patol Fiziol Eksp Ter; 1964; 8():37-9. PubMed ID: 14184390 [No Abstract] [Full Text] [Related]
39. Comparison of the action of ionizing radiations and biological alkylating agents (nitrogen mustards) at the cellular and sub-cellular level. ALEXANDER P Sci Rep Ist Super Sanita; 1961 Oct; 1():537-50. PubMed ID: 13860356 [No Abstract] [Full Text] [Related]